ArticleInternal medicine (Tokyo, Japan)2022
New-onset Type 1 Diabetes after COVID-19 mRNA Vaccination.
Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports.BMC endocrine disorders · 2023Pooled it
- Endocrine system after 2 years of COVID-19 vaccines: A narrative review of the literature.Frontiers in endocrinology · 2022Pooled it
- SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden.Diabetologia · 2026Article
- Autoimmune Phenomena and New-Onset Type 1 Diabetes Following SARS-CoV-2 Vaccination: A Personal Perspective.Immunity, inflammation and disease · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- Review
- New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.Internal medicine (Tokyo, Japan) · 2025Article
- Type I Diabetes-A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection.Reports (MDPI) · 2025Article
- An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.International journal of molecular epidemiology and genetics · 2025Review
- New Onset of Type 1 Diabetes Mellitus Post-COVID-19 Vaccine.Journal of medical cases · 2024Article
- Anti-MDA5 autoantibodies predict clinical dynamics of dermatomyositis following SARS-CoV-2 mRNA vaccination: a retrospective statistical analysis of case reports.Rheumatology international · 2024Review
- Review
- Type 1 diabetes mellitus following COVID-19 vaccination: a report of two cases and review of literature.Diabetology international · 2024Article
- Hypopituitarism with secondary adrenocortical insufficiency and arginine vasopressin deficiency due to hypophysitis after COVID-19 vaccination: a case report.BMC endocrine disorders · 2024Article
- Recent Patterns and Assessment of Long-term Complications followi ngSARS-CoV-2 Infection and Vaccination in the Context of Diabet esPrevalence among Blood Donors.Current diabetes reviews · 2024Article
- Internal Medicine Year in Review 2022.Internal medicine (Tokyo, Japan) · 2023Article
- Review
- Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.Diabetology international · 2023Article
- MicroRNAs Derived from Extracellular Vesicles: Keys to Understanding SARS-CoV-2 Vaccination Response in Cancer Patients?Cancers · 2023Review
- Molecular Mimicry and HLA Polymorphisms May Drive Autoimmunity in Recipients of the BNT-162b2 mRNA Vaccine: A Computational Analysis.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the ongoing coronavirus disease 2019 (COVID-19) pandemic, it is critical to ensure the safety of COVID-19 vaccines. We herein report a 51-year-old Japanese woman who developed acute-onset type 1 diabetes with diabetic ketoacidosis six weeks after receiving the first dose of a COVID-19 messenger ribonucleic acid (mRNA) vaccine. Laboratory tests indicated exhaustion of endogenous insulin secretion, a positive result for insulin autoantibody, and latent thyroid autoimmunity. Human leukocyte antigen typing was homozygous for DRB1*09:01-DQB1*03:03 haplotypes. This case suggests that COVID-19 vaccination can induce type 1 diabetes in some individuals with a genetic predisposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.